Drug Profile
WT1 protein-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center
Alternative Names: ATA 520; WT1 peptide-specific T-cells - Atara/MSKCC; WT1-CTL - Atara/MSKCC; WT1-sensitised T cells - Atara/MSKCC; WT1-targeted T cells - Atara/MSKCCLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia; Multiple myeloma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Refractory metastatic disease) in USA (IV, Infusion)
- 26 Feb 2021 Memorial Sloan Kettering Cancer Center in collaboration with Atara Biotherapeutics completes a phase I trial in Leukaemia (Second-line therapy or greater) in USA (IV, Infusion) (NCT00620633)